XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.25.1

WARRANTS | 12 Months Ended
--- | ---
Dec. 31, 2024
Warrants |
WARRANTS | Note 14. WARRANTS The Company’s outstanding Common Stock warrants are equity classified. As of December 31, 2024 and 2023, the Company had 12,298,124 and 4,649,952 warrants outstanding, respectively, to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price of $2.95 and expire at various dates through October 2029. During the year ended December 31, 2024, a total number of 1,066,767 warrants were exercised into an equivalent number of shares of Common Stock as compared to no warrants being exercised during the year ended December 31, 2023. The proceeds of the exercised warrants for the year ended December 31, 2024, was $1,343,390, compared to no proceeds during the year ended December 31, 2023. On March 8, 2024, the Company issued to certain investors (1) in a registered direct offering, 1,600,000 shares of the Company’s Common Stock and (2) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock, with an exercise price of $1.64 (collectively, the “Transaction”), which Transaction constitutes a Dilutive Issuance under the terms of the warrants. In addition, the placement agent was granted warrants to purchase 32,000 shares of Common Stock, with an exercise price of $1.64. On August 5, 2024, the Company entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company’s shares of Common Stock (the “Existing Warrants”). The exercising holders received in a private placement new unregistered warrants (the “New Warrants”) to purchase up to an aggregate of 1,302,082 shares of Common Stock with an exercise price of $1.50 per share, which are initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years from the date of such approval. In connection with the exercise of the Existing Warrants, the Company agreed to reduce the exercise price of the Existing Warrants from $1.64 to $1.25 per share. The exercise of the Existing Warrants and the issuance of the New Warrants occurred on August 5, 2024. The change in the exercise price of the Existing Warrants resulted in a fair value adjustment of $27,757 which was recorded to Additional paid-in capital for the exercised warrants. On August 5, 2024, the Company also entered into a securities purchase agreement with an institutional investor (the “Purchaser”), pursuant to which the Company issued to the Purchaser, (1) in a registered direct offering, 360,000 shares of Common Stock, and (2) in a concurrent private placement, warrants (the “Private Warrants”) to purchase an aggregate of 450,000 shares of Common Stock (the “Private Warrant Shares”), with an exercise price of $1.50 (collectively, the “Offering”). In addition, designees of the placement agent for the Offering were granted warrants to purchase an aggregate of up to 49,862 shares of Common Stock, with an exercise price of $1.50. On October 21, 2024, the Company issued (1) in a registered direct offering, 2,048,294 shares (the “Shares”) of the Company’s Common Stock, par value $0.007 per share, and (2) in a concurrent private placement, common warrants (the “Common Warrants”) to purchase an aggregate of 2,662,782 shares of Common Stock (the “Common Warrant Shares”), with an exercise price of $1.50, pursuant to a securities purchase agreement, dated October 18, 2024 with institutional investors (the “Purchasers”). Such registered direct offering and concurrent private placement are collectively referred to as the “Offerings.” In addition, designees of the placement agent for the Offering were granted warrants to purchase an aggregate of up to 61,448 shares of Common Stock, with an exercise price of $1.50. As of December 31, 2024, and prior to the Offering, there were tradeable warrants to purchase up to an aggregate of 1,601,255 shares of Common Stock outstanding and non-tradeable warrants to purchase an aggregate of up to 2,704,458 shares of Common Stock outstanding. SCHEDULE OF CLASS OF WARRANT
|  | Number of warrants issued |  |  | Weighted-average exercise price |  |  | Number of warrants exercised |  |  | Number of warrants outstanding |
Pre-IPO convertible notes |  |  | 2,900,904 |  |  | $ | 5.31 |  |  |  | — |  |  |  | 2,900,904 |
IPO tradeable |  |  | 2,326,835 |  |  |  | 3.06 |  |  |  | (725,580 | ) |  |  | 1,601,255 |
IPO non-tradeable |  |  | 3,015,464 |  |  |  | 3.06 |  |  |  | (311,006 | ) |  |  | 2,704,458 |
Direct offering March 8, 2024 |  |  | 1,600,000 |  |  |  | 1.64 |  |  |  | (1,066,667 | ) |  |  | 533,333 |
Placement agent direct offering March 8, 2024 |  |  | 32,000 |  |  |  | 1.64 |  |  |  | — |  |  |  | 32,000 |
Inducement/direct offering August 5, 2024 |  |  | 1,752,082 |  |  |  | 1.50 |  |  |  | — |  |  |  | 1,752,082 |
Placement agent direct offering August 5, 2024 |  |  | 49,862 |  |  |  | 1.50 |  |  |  | — |  |  |  | 49,862 |
Direct offering October 21, 2024 |  |  | 2,662,782 |  |  |  | 1.50 |  |  |  | — |  |  |  | 2,662,782 |
Placement agent direct offering October 21, 2024 |  |  | 61,448 |  |  |  | 1.50 |  |  |  | — |  |  |  | 61,448 |
Balance at December 31, 2024 |  |  | 14,401,377 |  |  | $ | 2.95 |  |  |  | (2,103,253 | ) |  |  | 12,298,124 |

X
- References No definition available. + Details
Name: | BIAF_DisclosureWarrantsAbstract
Namespace Prefix: | BIAF_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrants Disclosure [Text Block] + References No definition available. + Details
Name: | BIAF_WarrantsDisclosureTextBlock
Namespace Prefix: | BIAF_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration